GSK Discontinues Camlipixant After Mixed Phase 3 Results in Chronic Cough
The company will continue developing the drug for irritable bowel syndrome (IBS).
/ 20 items
#GSK↓
No Efficacy or Safety Issues: Achieve Life Sciences Gets FDA CRL for Cytisinicline
Achieve Life Sciences received an FDA Complete Response Letter for its cytisinicline NDA due to manufacturing issues at a former facility. No efficacy or safety deficiencies were identified.
GSK Buys Nuvalent for $10.6 Billion in Massive Cancer Drug Bet
The deal gives GSK two potential best-in-class lung cancer drugs and accelerates its oncology growth.
Myriad Genetics Scores FDA Nod for MyChoice CDx – The Only Approved HRD Test Guiding Zejula Therapy
Myriad Genetics' MyChoice CDx gains FDA approval as the only CDx to identify HRD-positive patients for Zejula maintenance in advanced ovarian cancer, boosting precision therapy.
Upstream Bio's Asthma Drug Hits Goal but Misses Top Hopes
Upstream Bio's Phase 2 trial for verekitug shows strong results in cutting asthma attacks, but only the every-12-week dose matches rivals. Stock dips as experts weigh in on future plans and competition.
FDA Rejects Moderna's mRNA Flu Vaccine Application
FDA refuses to review Moderna's innovative mRNA flu vaccine over clinical trial design concerns, sending shares down 7%. Company disputes decision citing prior agency approval.